Lung Cancer: The largest mid-DLL3 epidemiological study found that DLL3 expression was not associated with prognosis in patients with small cell lung cancer.

DLL3 is an important therapeutic target in the drugation of small cell lung cancer (SCLC) antibodies, and a recent study published in the journal Lung Cancer explores the clinical characteristics of the target.
this is the largest epidemiological study of DLL3 in the SCLC.
the study collected independent cancer samples from 1,073 patients, aged 66 and 64% male.
collected matching cytological specimens from 36 SCLC patients, of which 16 (44%) were male.
most patients had a PS score of 0-1, smokers or at least one treatment.
dLL3 in 85% of patients with 25% of the cutoff value, and 68% of patients with 75% as a cutoff value.
the combination of the samples collected, DLL3 cytological and histological expression consistency was 88% (n-17).
study also found that there was no difference in median OS in patients with positive and negative DLL3 expression, both at 9.5 months (negative DLL3 expression patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
in SCLC, DLL3 is significantly expressed in various disease staging strains and treatment departments.
DLL3 expression remained stable during treatment, consistent with available clinical trial data.
In this study, DLL3 had no prognosis effect on the total survival rate.
most SCLC patients expressed DLL3 protein, and dLL3 expression was not related to patient prognosis.
the median total survival of SCLC patients is very short and new treatments are urgently needed.
.